SCHEMBL1746153

SCHEMBL1746153

COC(=O)c1ccc(O)c(B2OC(C)(C)C(C)(C)O2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 4/20 0.54
CA1 P00915 4/20 0.54
CA2 P00918 4/20 0.54
CA7 P43166 4/20 0.54
CA9 Q16790 4/20 0.54
CA14 Q9ULX7 4/20 0.54
XDH P47989 2/20 0.54
KDM4E B2RXH2 4/20 0.49
ALDH1A1 P00352 4/20 0.49
HPGD P15428 4/20 0.49
HSD17B10 Q99714 4/20 0.49
MAPT P10636 4/20 0.49
LMNA P02545 3/20 0.49
ALOX15 P16050 3/20 0.49
ALOX12 P18054 3/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
TP53 P04637 2/20 0.49
HTT P42858 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18145744 0.88 CA1 (0.54) CA12CA1CA2CA7CA9
SCHEMBL960031 0.85 ALDH1A1 (0.43) CA12CA1CA2CA7CA9
SCHEMBL5442364 0.85 KDM4E (0.50) CA12CA1CA2CA7CA9
SCHEMBL3453725 0.85 KDM4E (0.50) CA12CA1CA2CA7CA9
SCHEMBL21216768 0.84 CA1 (0.41) CA12CA1CA2CA7CA9
SCHEMBL938124 0.84 CA12 (0.41) CA12CA1CA2CA7CA9
SCHEMBL3336720 0.84 ALDH1A1 (0.48) CA12CA1CA2CA7CA9
SCHEMBL5899519 0.84 MAPT (0.50) CA12CA1CA2CA7CA9
SCHEMBL18371630 0.83 PKM (0.44) CA1CA2CA9KDM4EMAPT
SCHEMBL23795687 0.83 UCHL1 (0.41) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240325409-A1 Fused Heterotetracyclic Antiviral Agents ENANTA PHARMACEUTICALS, INC. 2024-10-03 US disclosed
WO-2024182271-A1 FUSED HETEROTETRACYCLIC ANTIVIRAL AGENTS ENANTA PHARMACEUTICALS, INC. (US) 2024-09-06 WO disclosed
US-20230026651-A1 AMINO-PYRIMIDINE SKELETAL MUSCLE MODULATORS CYTOKINETICS, INC. 2023-01-26 US disclosed
US-11369565-B2 Amino-pyrimidine skeletal muscle modulators CYTOKINETICS, INC. (US) 2022-06-28 US disclosed
US-20210045997-A1 AMINO-PYRIMIDINE SKELETAL MUSCLE MODULATORS CYTOKINETICS, INC. 2021-02-18 US disclosed
US-10765624-B2 Amino-pyrimidine skeletal muscle modulators CYTOKINETICS, INC. (US) 2020-09-08 US disclosed
EP-3698795-A1 CERTAIN AMINO-PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE Cytokinetics, Inc. (US) 2020-08-26 EP disclosed
EP-3127540-B1 CERTAIN AMINO-PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE CYTOKINETICS INC (US) 2020-01-29 EP disclosed
US-20190307677-A1 AMINO-PYRIMIDINE SKELETAL MUSCLE MODULATORS CYTOKINETICS INC (US) 2019-10-10 US disclosed
US-10272030-B2 Amino-pyrimidine skeletal muscle modulators CYTOKINETICS, INC. (US) 2019-04-30 US disclosed
WO-2015126376-A1 PYRAZOLOPYRIMIDINE MACROCYCLES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BRISTOL-MYERS SQUIBB COMPANY (US) 2015-08-27 WO disclosed
US-9018223-B2 Certain amino-pyrimidines, compositions thereof, and methods for their use CYTOKINETICS, INC. (US) 2015-04-28 US disclosed
US-8962632-B2 Certain amino-pyrimidines, compositions thereof, and methods for their use CYTOKINETICS, INC. (US) 2015-02-24 US disclosed
US-20140206709-A1 CERTAIN AMINO-PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE CYTOKINETICS, INC. 2014-07-24 US disclosed
US-20130123289-A1 CERTAIN AMINO-PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE CYTOKINETICS, INC. (US) 2013-05-16 US disclosed
EP-2560653-A1 CERTAIN AMINO-PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE Cytokinetics, Inc. (US) 2013-02-27 EP disclosed
WO-2011133888-A1 CERTAIN AMINO-PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE CYTOKINETICS, INC. (US) 2011-10-27 WO disclosed
EP-2380890-A1 New 7,8-dihydro-1,6-naphthyridin-5(6h)-one-derivatives as PDE4 inhibitors Almirall, S.A. (ES) 2011-10-26 EP disclosed
EP-2380890-A1 New 7,8-dihydro-1,6-naphthyridin-5(6h)-one-derivatives as PDE4 inhibitors Almirall, S.A. (ES) 2011-10-26 EP disclosed
US-20110253549-A1 WASHING APPARATUS AND METHOD OF DEODORIZING WASHING WATER KANNO MINORU 2011-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11369565-B2 Amino-pyrimidine skeletal muscle modulators MUSK, PYGM, TNNC1 CA12 4859/4885CA1 4681/4885CA2 3016/4885
US-10765624-B2 Amino-pyrimidine skeletal muscle modulators MUSK, PYGM, TNNC1 CA12 4873/4885CA1 4783/4885CA2 3081/4885
US-20230026651-A1 AMINO-PYRIMIDINE SKELETAL MUSCLE MODULATORS MUSK, PYGM, TNNC1 CA12 4873/4885CA1 4783/4885CA2 3081/4885
US-10272030-B2 Amino-pyrimidine skeletal muscle modulators MUSK, PYGM, TNNC1 CA12 4873/4885CA1 4783/4885CA2 3081/4885
US-20190307677-A1 AMINO-PYRIMIDINE SKELETAL MUSCLE MODULATORS MUSK, PYGM, TNNC1 CA12 4873/4885CA1 4783/4885CA2 3081/4885
US-20210045997-A1 AMINO-PYRIMIDINE SKELETAL MUSCLE MODULATORS MUSK, PYGM, TNNC1 CA12 4859/4885CA1 4681/4885CA2 3016/4885
US-20140206709-A1 CERTAIN AMINO-PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE HPRT1, TYMP, TYMS CA12 4722/4885CA1 4608/4885CA2 4099/4885
US-20240325409-A1 Fused Heterotetracyclic Antiviral Agents HAVCR2, HDGF, SLC10A1 CA12 3112/4885CA1 3640/4885CA2 3617/4885
US-20130123289-A1 CERTAIN AMINO-PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE HPRT1, TYMP, TYMS CA12 4722/4885CA1 4608/4885CA2 4099/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.